🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity · Phase II

Metabolic & obesity programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
210

Quick answer

Metabolic & obesity Phase II programs: NovaPharmaNews indexes 210 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 1 of 5

  1. 0.59 mg fluocinolone acetonide intravitreal implant

    Bausch & Lomb Incorporated

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial

  2. 10mg DS-8500a tablet

    Daiichi Sankyo

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  3. 2HPβCD

    ZyVersa Therapeutics

    Diabetic Kidney Disease

    phase 2 small molecule terminated

    1 trial

  4. 3-V Bioscience-2640

    Sagimet Biosciences

    Metabolic Syndrome

    phase 2 small molecule completed

    1 trial

  5. 4D-150 IVT

    4D Molecular Therapeutics

    Diabetic Macular Edema

    phase 2 mab active

    1 trial

  6. 5% Bisphosphocin Topical Gel

    Lakewood-Amedex Biotherapeutics

    Chronic Diabetic Foot Ulcers

    phase 2 small molecule terminated

    1 trial

  7. 5% Nu-3 gel

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infection

    phase 2 small molecule active

    1 trial

  8. 75 mg LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  9. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

    Sanofi-aventis Healthcare Pty Ltd

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  10. ALG-055009

    Aligos Therapeutics

    NASH

    phase 2 small molecule completed

    1 trial

  11. ALN-2232

    Alnylam Netherlands B.V.

    Obesity

    phase 2 small molecule active

    1 trial

  12. ALN-4324

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  13. ALN-4324

    Alnylam Netherlands B.V.

    Obese or Overweight Healthy Volunteers

    phase 2 small molecule active

    1 trial

  14. ALN-ANG3

    Regeneron UK Limited

    Diabetic Kidney Disease (DKD)

    phase 2 small molecule active

    1 trial

  15. ALN-CIDEB

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 2 small molecule active

    1 trial

  16. ALN-HSD

    Regeneron UK Limited

    Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    phase 2 small molecule active

    1 trial

  17. ALN-KHK

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule terminated

    1 trial

  18. ALN-PNP

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    phase 2 small molecule active

    1 trial

  19. AMG 133, Placebo for AMG 133

    Amgen

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  20. ARD-101

    Ark Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  21. ARO-ALK7

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

  22. ARO-INHBE

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

  23. ASC30 tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule active

    1 trial

  24. AT-1501

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  25. AT-1501 IV Infusion

    Eledon Pharmaceuticals

    Brittle Type 1 Diabetes Mellitus

    phase 2 mab terminated

    1 trial

  26. AZD5004, AZD5004, AZD5004, Rybelsus 14 mg tablets, Placebo to match AZD5004 (PTM) film-coated tablets, Rybelsus 7 mg tablets, Rybelsus 3 mg tablets

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  27. AZD5004, Placebo to match AZD5004 film coated tablet, AZD5004, AZD5004

    AstraZeneca AB

    Participants living with Obesity or Overweight with at least 1 comorbidity

    phase 2 small molecule active

    1 trial

  28. Aflibercept

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 2 small molecule completed

    1 trial

  29. Aldesleukin

    United Therapeutics Europe Ltd

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  30. Aleniglipron

    Structure Therapeutics

    Obese

    phase 2 small molecule active

    1 trial

  31. Aleniglipron or Placebo

    Structure Therapeutics

    Obesity, Overweight, or Chronic Weight Management

    phase 2 small molecule active

    2 trials

  32. Antimicrobial agent

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Ulcers (DFUs)

    phase 2 small molecule active

    1 trial

  33. BI 1815368, BI 1815368 Placebo, BI 1815368

    Boehringer Ingelheim

    Centre-involved diabetic macular edema

    phase 2 small molecule active

    1 trial

  34. BI 456906

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  35. BI 764524, Sham Injection Procedure

    Boehringer Ingelheim

    Diabetic retinopathy

    phase 2 small molecule active

    1 trial

  36. Bempedoic acid + Ezetimibe FDC Oral Tablet

    Esperion Therapeutics

    Diabetes

    phase 2 small molecule completed

    1 trial

  37. Bicifadine

    XTL BIOPHARMACEUTICALS LTD

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  38. Bicifadine

    XTL BIOPHARMACEUTICALS LTD

    Chronic Peripheral Neuropathy Pain in Diabetics

    phase 2 small molecule terminated

    1 trial

  39. Bisphosphocin Nu-3

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  40. Bivamelagon

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  41. CF102

    Can-Fite BioPharma

    Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  42. CLBS03 Low Dose

    LISATA THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 2 mab completed

    1 trial

  43. CRV431 75mg

    Hepion Pharmaceuticals

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  44. CS-3150

    Daiichi Sankyo

    Diabetic Nephropathy

    phase 2 small molecule completed

    1 trial

  45. CSG452 (Tofogliflozin) placebo, pemafibrate, K-877 ER (Pemafibrate) placebo, TOFOGLIFLOZIN

    The George Institute

    Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

    phase 2 small molecule active

    1 trial

  46. CX11, Placebo to cx11 40 mg, CX11, Placebo to cx11 80 mg

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  47. CYCLIZINE , CALCIUM CARBONATE , Placebo for azd9550, CALCIUM CITRATE , CALCIUM GLUCONATE , Placebo for azd6234, Placebo for azd9550, AZD6234, GLUCOSE , GLUCAGON , ONDANSETRON

    AstraZeneca AB

    Investigating obesity or overweight condition correlated to many co-morbidities

    phase 2 small molecule active

    1 trial

  48. Canakinumab 150 mg

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many metabolic & obesity Phase II programs exist?

210 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.